stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) P/S ratio
As of 5 November 2026, AstraZeneca PLC (AZN) trades at a P/S ratio of 4.7×. Over the past ten years it has ranged from 2.6× (December 2016) to 6.9× (March 2015); the current reading is higher than 59% of that period. That is above the Drug Manufacturers General industry median of 3.5× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 4.6× | 24.12% |
| FY2024 | 3.7× | (16.97%) |
| FY2023 | 4.5× | (5.70%) |
| FY2022 | 4.8× | 8.47% |
| FY2021 | 4.4× | (11.81%) |
| FY2020 | 5.0× | (7.61%) |
| FY2019 | 5.4× | 23.69% |
| FY2018 | 4.4× | 12.72% |
| FY2017 | 3.9× | 26.82% |
| FY2016 | 3.0× | (12.26%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 4.0× | (16.24%) |
| Jun 2026 | 4.8× | (5.18%) |
| Mar 2026 | 5.1× | 9.22% |
| Dec 2025 | 4.6× | 16.02% |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| BMY Bristol Myers Squibb Company compare | 2.6× |
| PFE Pfizer Inc. compare | 2.7× |
| NVO Novo Nordisk A/S compare | 3.5× |
| AZN AstraZeneca PLC | 4.7× |
| NVS Novartis AG compare | 5.4× |
| MRK Merck & Co., Inc. compare | 5.4× |
| AMGN Amgen Inc. compare | 6.4× |
| GILD Gilead Sciences, Inc. compare | 6.7× |
| ABBV AbbVie Inc. compare | 7.7× |
| Drug Manufacturers General industry median | 3.5× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on AZN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement